Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.

Ligand Pharmaceuticals Incorporated

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.

HBM Holdings Limited

Ligand is a biopharma technology and capital partner that provides technology and financing solutions to advance tomorrow's medicines.

Metric
Company Name	Ligand Pharmaceuticals Incorporated	HBM Holdings Limited
Symbol	LGND	2.14K
MSH ID	COM:LIGAND	COM:HARBOURBIOMED
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	CN
Stage		Series C
Employee Count	58	177
Website	ligand.com	harbourbiomed.com
LinkedIn		harbour-biomed
Founders

Metric
Market Cap	1.73B	131.44M
Enterprise Value
Monthly Web Traffic	5.98K	603
Web Traffic Growth	3.30	-0.14
Valuation
Raised Capital	650M	102.80M

Metric
Revenue	131.31M	89.50M
Revenue (LTM)
Revenue (NTM)
Gross Profit	119.75M	87.47M
EBITDA	51.22M	26.65M
Operating Income	9.82M	21.83M
Net Income	52.15M	22.80M
EPS	3.02	0.03
Diluted EPS	2.94	0.03
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.94	1.00
Operating Profit Margin	0.07	0.28
EBITDA Margin	0.39	0.30
Net Profit Margin	0.79	0.31
Return on Equity	0.18	0.21
Return on Assets	0.10	0.10
Return on Capital Employed	0.02	0.13

COM:LIGAND

Ligand

Last Close

116.55

22/11 21:00

Market Cap

1.73B

Beta: -

Volume Today

90.76K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	76.86	-1.03
P/B Ratio	1.95	1.52
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	17.00	2.57
EV Multiple	74.08	12.92

Metric
Days Sales Outstanding	93.12
Days Payables Outstanding	156.97	61.85K
Days Inventory Outstanding	830.44	4.29K
Operating Cycle	939.71	4.34K
Cash Conversion Cycle	484.52	-536.87
Asset Turnover	0.16	0.39

Metric
Operating Cash Flow	49.58M
Free Cash Flow	-4.27M
Cash Flow to Debt	8.04	0.32
Operating Cash Flow/Sales	0.42	0.29
Free Cash Flow Yield	0.07	-0.76

Metric
Cash & Equivalents	22.95M	140.32M
Accounts Receivable	-2.60M
Inventory	23.97M	1
Goodwill	103.37M
Debt to Capitalization	0.01	0.45
Debt to Assets	0.01	0.39
Current Ratio	13.66	2.79
Quick Ratio	19.51	3.44

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.28	0.14
R&D to Revenue	0.18	3.32
SG&A to Revenue	0.44	0.25